



INDIAN PHARMACOPOEIA COMMISSION

National Coordination Centre- Pharmacovigilance Programme of India (PvPI)

MINISTRY OF HEALTH & FAMILY WELFARE, GOVERNMENT OF INDIA

SECTOR-23, RAJ NAGAR, GHAZIABAD- 201 002.

Tel No: 0120- 2783392, 2783400, 2783401, Fax: 0120-2783311

e-mail: pypi.ipc@gov.in, ipclab@vsnl.net, Web: www.ipc.gov.in

File No. IPC/NCC-PvPI/DSA/2017-18/03

March 2017

Drug Safety Alerts

The preliminary analysis of SUSARs from the PvPI database reveals that the following drugs are associated with the risks as given below.

Table

Sl. No	Suspected Drugs	Indication	Adverse Reactions
1	Deferasirox	Treatment of chronic iron overload in patients with non-transfusion dependent thalassemia (NTDT) syndromes	Osteoporosis
2	Ambroxol	All forms of tracheobronchitis, emphysema with bronchitis pneumoconiosis, chronic inflammatory pulmonary conditions, bronchiectasis, bronchitis with bronchospasm asthma	Lacrimation
3	Lurasidone	Treatment of Patients with Schizophrenia	Thrombocytopenia
4	Etoricoxib	Short term use in acute painful condition	Skin Hyperpigmentation

Health care professionals, Patients/Consumers are advised to closely monitor the possibility of the above adverse events associated with the use of above drugs. If such events are encountered please report to the NCC-PvPI either by filling of Suspected Adverse Drug Reactions Reporting Form/ Medicines Side Effect Reporting Form for Consumer (<http://www.ipc.gov.in>) or by PvPI Helpline No. **1800-180-3024**.

"Let us join hands with PvPI to ensure patients safety"

ADR Reporting Help line (Toll Free): 1800-180-3024